<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H7F4B7169DAE040AE9B30B43C704D6B75" public-private="public" bill-type="olc"> 
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 2416 IH: To amend the Federal Food, Drug, and Cosmetic Act to evaluate the potential use of evidence from clinical experience to help support the approval of new indications for approved drugs, and for other purposes.</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-05-19</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code> 
<congress>114th CONGRESS</congress>
<session>1st Session</session>
<legis-num>H. R. 2416</legis-num> 
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber> 
<action> 
<action-date date="20150519">May 19, 2015</action-date> 
<action-desc><sponsor name-id="B001248">Mr. Burgess</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
</action> 
<legis-type>A BILL</legis-type> 
<official-title>To amend the Federal Food, Drug, and Cosmetic Act to evaluate the potential use of evidence from clinical experience to help support the approval of new indications for approved drugs, and for other purposes.</official-title> 
</form> 
<legis-body id="H53A0274B041749F890CC13AAC60D719D" style="OLC"> 
<section id="H14B84722B5D14A1DAB1DC2392366BF03" commented="no" section-type="section-one"><enum>1.</enum><header>Utilizing evidence from clinical experience</header><text display-inline="no-display-inline">Chapter V of the Federal Food, Drug, and Cosmetic Act is amended by inserting after section 505E of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355f">21 U.S.C. 355f</external-xref>) the following:</text> <quoted-block style="OLC" id="HBE3A6058A90F4897BB83A88B3823EAF4" display-inline="no-display-inline"> <section id="HEC93215FEAC64857ACB9DEDF18324463" commented="no"><enum>505F.</enum><header>Utilizing evidence from clinical experience</header> <subsection id="HF621083259E041D3A6E144A2AA502032" commented="no"><enum>(a)</enum><header>In general</header><text>The Secretary shall establish a program to evaluate the potential use of evidence from clinical experience—</text> 
<paragraph id="H38E38B0263C94088AF56F9556FA1BF5A" commented="no"><enum>(1)</enum><text>to help support the approval of a new indication for a drug approved under section 505(b); and</text></paragraph> <paragraph id="HCBAA22EF565E4FC994977140031EEDB2" commented="no"><enum>(2)</enum><text>to help support or satisfy post-approval study requirements.</text></paragraph></subsection> 
<subsection id="H5AF87DD348624AEBBF322A363E053D70" commented="no"><enum>(b)</enum><header>Evidence from clinical experience defined</header><text>In this section, the term <quote>evidence from clinical experience</quote> means data regarding the usage, or potential benefits or risks, of a drug derived from sources other than randomized clinical trials, including from observational studies, registries, and therapeutic use.</text></subsection> <subsection id="H2EEAC414349848818C0168331BA710C9" commented="no"><enum>(c)</enum><header>Program framework</header> <paragraph id="HE34E0FBBFBA94B0DBFE975A5CDE4D8D7" commented="no"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 18 months after the date of enactment of this section, the Secretary shall establish a draft framework for implementation of the program under this section.</text></paragraph> 
<paragraph id="HB72EB5D2BD95443A903C0C59D6AE7F76" commented="no"><enum>(2)</enum><header>Contents of framework</header><text>The framework shall include information describing—</text> <subparagraph id="HE4C5D1E86F6F411EA404D9CB2A5EEE2F" commented="no"><enum>(A)</enum><text>the current sources of data developed through clinical experience, including ongoing safety surveillance, registry, claims, and patient-centered outcomes research activities;</text></subparagraph> 
<subparagraph id="H718256364DF44B1BA8E0DA36BF9C6339" commented="no"><enum>(B)</enum><text>the gaps in current data collection activities;</text></subparagraph> <subparagraph id="HAED06FDE49204153A076206C4B4CF52D" commented="no"><enum>(C)</enum><text>the current standards and methodologies for collection and analysis of data generated through clinical experience; and</text></subparagraph> 
<subparagraph id="H4014E5EF42D14AA5A665F4859852AE52" commented="no"><enum>(D)</enum><text>the priority areas, remaining challenges, and potential pilot opportunities that the program established under this section will address.</text></subparagraph></paragraph> <paragraph id="H71161D993B9649C19A2EB6EE239C7796" commented="no"><enum>(3)</enum><header>Consultation</header> <subparagraph id="H7D30A1AC3E074675820895B318326CAA"><enum>(A)</enum><header>In general</header><text>In developing the program framework under this subsection, the Secretary shall consult with regulated industry, academia, medical professional organizations, representatives of patient advocacy organizations, disease research foundations, and other interested parties.</text></subparagraph> 
<subparagraph id="H09285BD5D8E84C88A203B54EF73E7B55"><enum>(B)</enum><header>Process</header><text display-inline="yes-display-inline">The consultation under subparagraph (A) may be carried out through approaches such as—</text> <clause id="H9CA5E008A4C3451AB00D68FB1292736B"><enum>(i)</enum><text>a public-private partnership with the entities described in such subparagraph, in which the Secretary may participate; or</text></clause> 
<clause id="HD98834591A914249A02B3B4B2D7D3A70"><enum>(ii)</enum><text>a contract, grant, or other arrangement, as determined appropriate by the Secretary with such a partnership or an independent research organization.</text></clause></subparagraph></paragraph></subsection> <subsection id="HD7AE84D9629540E4A69CE1E595F65CE8" commented="no"><enum>(d)</enum><header>Program implementation</header><text>The Secretary shall, not later than 24 months after the date of enactment of this section and in accordance with the framework established under subsection (c), implement the program to evaluate the potential use of evidence from clinical experience.</text></subsection> 
<subsection id="HA00C49EAC1E54E9E8D2E705029734961" commented="no"><enum>(e)</enum><header>Guidance for industry</header><text display-inline="yes-display-inline">The Secretary shall—</text> <paragraph id="HD74D3387D99048419CE6CEB991C0CBC2" commented="no"><enum>(1)</enum><text>utilize the program established in subsection (d), its activities, and any subsequent pilots or written reports, to inform a guidance for industry on—</text> 
<subparagraph id="H5F35324CE0FC4BB49270009BF9C178BF" commented="no"><enum>(A)</enum><text>the circumstances under which sponsors of drugs and the Secretary may rely on evidence from clinical experience for the purposes described in subsections (a)(1) or (a)(2); and</text></subparagraph> <subparagraph id="HC2E8DF737A254F13A9704EABD9291BD2" commented="no"><enum>(B)</enum><text>the appropriate standards and methodologies for collection and analysis of evidence from clinical experience submitted for such purposes; </text></subparagraph></paragraph> 
<paragraph id="H3D09EF1013CD46BB91D0F7AB7C6F390B" commented="no"><enum>(2)</enum><text>not later than 36 months after the date of enactment of this section, issue draft guidance for industry as described in paragraph (1); and</text></paragraph> <paragraph id="H219640EA8C404027A3D3E9142ED6B40A" commented="no"><enum>(3)</enum><text>not later than 48 months after the date of enactment of this section, after providing an opportunity for public comment on the draft guidance, issue final guidance.</text></paragraph></subsection> 
<subsection id="HCEBC2689338B478786024EFEE254ACD1" commented="no"><enum>(f)</enum><header>Rule of construction</header> 
<paragraph id="HBF04BB8537AF4A19B5AA3441C1070E74" commented="no"><enum>(1)</enum><text>Subject to paragraph (2), nothing in this section prohibits the Secretary from using evidence from clinical experience for purposes not specified in this section, provided the Secretary determines that sufficient basis exists for any such non-specified use.</text></paragraph> <paragraph id="H6D2363FF32BF4C72A848D208054A9CF2" commented="no"><enum>(2)</enum><text>This section shall not be construed to alter—</text> 
<subparagraph id="H4EBD8984C2DF4A34833948A94773187B" commented="no"><enum>(A)</enum><text>the standards of evidence under—</text> <clause id="H5063BAAC4FF1419C8C21080D198F65F1" commented="no"><enum>(i)</enum><text>subsection (c) or (d) of section 505, including the substantial evidence standard in such subsection (d); or</text></clause> 
<clause id="H785D89A0D5534507A7D14827437248F2" commented="no"><enum>(ii)</enum><text>section 351(a) of the Public Health Service Act; or</text></clause></subparagraph> <subparagraph id="HE33937610B8F4F79BE9A397F62BE454C" commented="no"><enum>(B)</enum><text>the Secretary’s authority to require post-approval studies or clinical trials, or the standards of evidence under which studies or trials are evaluated.</text></subparagraph></paragraph></subsection></section> <after-quoted-block>.</after-quoted-block></quoted-block></section>
</legis-body> 
</bill> 

